A concept trial of ADP-ribose inhibitor, Olaparib was carried out in patients with BRCA1 and BRCA2 mutations detected. This inhibition showed a favorable therapeutic index for targeted treatment in breast cancer patients from Australia, Germany, Spain, Sweden, UK, and the USA. Here, BRCA2 is linked to breast cancer.